Scientists Develop Powder for Emergency Control of Severe Bleeding
🩸 What Is AGCL Powder?
Scientists from the Korea Institute of Science and Technology (KIST) have developed AGCL powder — a novel hemostatic agent for emergency control of severe bleeding. In preclinical studies, it significantly reduced blood loss and accelerated hemostasis compared to TachoSil, one of the clinical standards for bleeding control.
Upon contact with blood, the powder reacts with calcium ions and transforms into a dense hydrogel within seconds, physically sealing the wound.
Seals wounds in seconds
7x its weight in blood
>99.9% bacterial reduction
💡 Key Innovation: The powder is suitable for deep, large, and irregular wounds — unlike conventional bandages that are limited to flat, accessible surfaces.
⚙️ How the Technology Works
1. Contact with Blood
AGCL powder reacts with calcium ions present in blood upon application to the wound.
2. Hydrogel Formation
Transforms into a dense hydrogel within seconds, physically sealing the wound and stopping blood flow.
3. Blood Absorption
Absorbs up to 7 times its own weight in blood while maintaining a secure seal on the tissue.
📊 Key Research Findings
Absorbs nearly 7 times its own weight in blood
Reduces viable bacteria by more than 99.9%
Maintains properties during storage for up to 24 months
💡 Safety Profile: The powder showed minimal damage to red blood cells, exhibited no cell toxicity, and accelerated tissue regeneration, new blood vessel formation, and collagen synthesis.
📊 AGCL vs TachoSil — Comparison
| Parameter | AGCL Powder | TachoSil (Standard) |
|---|---|---|
| Hemostatic Speed | Faster | Standard |
| Blood Loss Reduction | Superior | Standard |
| Wound Suitability | Deep, large, irregular | Flat, accessible |
| Antibacterial Effect | >99.9% | Limited |
| Tissue Regeneration | Enhanced | Standard |
🏥 Potential Applications
Following further trials, the technology could be applied in:
Intraoperative bleeding control
Trauma and accident response
Field and mass casualty situations
Combat casualty care
❓ Frequently Asked Questions
What is AGCL powder?
AGCL powder is a novel hemostatic agent developed by Korean scientists that rapidly stops severe bleeding by forming a dense hydrogel upon contact with blood.
How does AGCL powder work?
Upon contact with blood, the powder reacts with calcium ions and transforms into a dense hydrogel within seconds, physically sealing the wound and absorbing up to 7 times its weight in blood.
Is AGCL powder safe?
Preclinical studies showed it causes minimal damage to red blood cells, exhibits no cell toxicity, and reduces viable bacteria by more than 99.9%.
When will AGCL powder be available for patients?
The technology is currently in preclinical research. Further clinical trials are needed before it can be approved for use in surgery, emergency medicine, and trauma care.
How does AGCL compare to existing products?
In preclinical studies, AGCL powder significantly reduced blood loss and accelerated hemostasis compared to TachoSil, one of the current clinical standards for bleeding control.
📚 References & Resources
- Korea Institute of Science and Technology — Official Website
- PubMed — Hemostatic Powder Research
- WHO — Trauma and Emergency Care
- FDA — Hemostatic Devices
⚠️ Medical Disclaimer
This content is for informational and educational purposes only. AGCL powder is currently in preclinical research and is not yet available for clinical use. Always consult qualified healthcare professionals for medical advice, diagnosis, or treatment.
© 2026 BuyAllMD.com — Evidence-Based Medical Technology News
